Outlook Therapeutics Faces FDA Hurdles for Retina Treatment
Event summary
- Outlook Therapeutics received a Complete Response Letter (CRL) in December 2025 for ONS-5010/LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation for wet AMD.
- A Type A meeting with the FDA was held to clarify the CRL's concerns regarding substantial evidence of effectiveness.
- The NORSE TWO Phase 3 trial demonstrated statistically significant improvements in visual acuity, while NORSE EIGHT provided confirmatory efficacy and safety data.
- LYTENAVA™ has already received Marketing Authorization in the EU and UK.
- Outlook Therapeutics is evaluating regulatory options to pursue FDA approval in the US.
The big picture
Outlook Therapeutics is attempting to bring a domestically manufactured, FDA-approved version of bevacizumab to the US market, a move that could disrupt the existing ophthalmology landscape dominated by larger competitors. The FDA’s scrutiny highlights the increasing rigor in approving novel formulations of established drugs, particularly in a market sensitive to cost and patient access. The company's prior success in Europe provides a template, but US regulatory pathways often differ significantly.
What we're watching
- Regulatory Headwinds
- The FDA’s specific concerns regarding ‘substantial evidence of effectiveness’ remain unclear, and the company’s ability to address them will dictate the timeline for potential approval.
- Execution Risk
- Outlook’s evaluation of regulatory options could lead to costly and time-consuming additional trials or data submissions, potentially impacting the company’s financial resources.
- Commercialization
- Even with FDA approval, securing pricing and reimbursement in the US market will be critical for ONS-5010/LYTENAVA™ to achieve commercial success, mirroring the challenges faced in Europe.
Related topics